[go: up one dir, main page]

RU2002122174A - Способ профилактики и лечения заболевания, опосредуемого csbp/rk/p38 киназой, и способ лечения воспаления - Google Patents

Способ профилактики и лечения заболевания, опосредуемого csbp/rk/p38 киназой, и способ лечения воспаления Download PDF

Info

Publication number
RU2002122174A
RU2002122174A RU2002122174/14A RU2002122174A RU2002122174A RU 2002122174 A RU2002122174 A RU 2002122174A RU 2002122174/14 A RU2002122174/14 A RU 2002122174/14A RU 2002122174 A RU2002122174 A RU 2002122174A RU 2002122174 A RU2002122174 A RU 2002122174A
Authority
RU
Russia
Prior art keywords
disease
atherosclerosis
arthritis
mammal
csbp
Prior art date
Application number
RU2002122174/14A
Other languages
English (en)
Inventor
Джерри Лерой ЭДАМС (US)
Джерри Лерой ЭДАМС
Тимоти Ф. ГАЛЛАГЕР (US)
Тимоти Ф. ГАЛЛАГЕР
Рави Шанкер ГАРИДЖИПАТИ (US)
Рави Шанкер ГАРИДЖИПАТИ
Джеффри Чарльз БОЕМ (US)
Джеффри Чарльз БОЕМ
Джозеф СИСКО (US)
Джозеф Сиско
Зи-Кианг ПЕНГ (US)
Зи-Кианг ПЕНГ
Джон Чеунг-Лун ЛИ (US)
Джон Чеунг-Лун ЛИ
Original Assignee
Смитклайн Бичам Корпорейшн (US)
Смитклайн Бичам Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Смитклайн Бичам Корпорейшн (US), Смитклайн Бичам Корпорейшн filed Critical Смитклайн Бичам Корпорейшн (US)
Publication of RU2002122174A publication Critical patent/RU2002122174A/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00Preparation of sulfones; Preparation of sulfoxides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/38One sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)

Claims (4)

1. Способ профилактики и лечения опосредуемого CSBP/RK/p38 киназой заболевания у млекопитающего, нуждающегося в этом, который включает введение указанному млекопитающему эффективного количества 5-(4-пиридил)-4-(4-фторфенил)-1-(4-пиперидинил)-имидазола, или его фармацевтически приемлемой соли.
2. Способ по п.1, где заболевание выбрано из группы, включающей ревматоидный артрит, ревматоидный спондилит, остеоартрит, псориатический артрит, травматический артрит, артрит при краснухе, острый синовит, артрит при подагре и другие артритные состояния, сепсис, септический шок, эндотоксический шок, грамм-отрицательный сепсис, синдром токсического шока, астму, синдром недомогания у взрослых при респираторном заболевании, хроническое легочное воспалительное заболевание, силикоз, легочный саркоидоз, заболевания резорбции костных тканей, остеопороз, реакцию на прививку, отторжение алломорфных прививок, повышенную температуру, приступы стенокардии, сердечное и почечное реперфузионное повреждение, тромбоз, гломерулонефрит, церебральную малярию, диабет и β-клетки поджелудочной железы, рассеянный склероз, дегенерацию мышц, атеросклероз, болезнь Альцгеймера, экзему, псориаз, солнечный ожог, конъюнктивит, болезнь Крона, язвенный колит или воспалительное заболевание кишечника.
3. Способ по п.2, где заболевание выбрано из группы, включающей экзему, псориаз, солнечный ожог и конъюнктивит.
4. Способ лечения воспаления у млекопитающего, нуждающегося в этом, включающий введение указанному млекопитающему эффективного количества 5-(4-пиридил)-4-(4-фторфенил)-1-(4-пиперидинил) имидазола или его фармацевтически приемлемой соли.
RU2002122174/14A 1995-01-09 2002-08-15 Способ профилактики и лечения заболевания, опосредуемого csbp/rk/p38 киназой, и способ лечения воспаления RU2002122174A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36996495A 1995-01-09 1995-01-09
US08/369,964 1995-01-09
US08/472,366 US5593992A (en) 1993-07-16 1995-06-07 Compounds
US08/472,366 1995-06-07

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU97113753/04A Division RU2196139C2 (ru) 1995-01-09 1996-01-11 1,4,5-тризамещенные производные имидазола, способы их получения и фармацевтическая композиция на их основе

Publications (1)

Publication Number Publication Date
RU2002122174A true RU2002122174A (ru) 2004-02-27

Family

ID=27004764

Family Applications (2)

Application Number Title Priority Date Filing Date
RU97113753/04A RU2196139C2 (ru) 1995-01-09 1996-01-11 1,4,5-тризамещенные производные имидазола, способы их получения и фармацевтическая композиция на их основе
RU2002122174/14A RU2002122174A (ru) 1995-01-09 2002-08-15 Способ профилактики и лечения заболевания, опосредуемого csbp/rk/p38 киназой, и способ лечения воспаления

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU97113753/04A RU2196139C2 (ru) 1995-01-09 1996-01-11 1,4,5-тризамещенные производные имидазола, способы их получения и фармацевтическая композиция на их основе

Country Status (33)

Country Link
US (5) US5593992A (ru)
EP (2) EP1264827A1 (ru)
JP (2) JP3330952B2 (ru)
CN (1) CN1138546C (ru)
AP (1) AP1270A (ru)
AR (1) AR002267A1 (ru)
AT (1) ATE254613T1 (ru)
AU (1) AU705207C (ru)
BG (1) BG63769B1 (ru)
BR (1) BR9606904A (ru)
CA (1) CA2209938A1 (ru)
CZ (1) CZ215897A3 (ru)
DE (1) DE69630777T2 (ru)
DK (1) DK0809499T3 (ru)
DZ (1) DZ1961A1 (ru)
ES (1) ES2210348T3 (ru)
FI (1) FI972901L (ru)
HU (1) HUP9702409A3 (ru)
ID (3) ID23273A (ru)
IL (7) IL134322A (ru)
IN (3) IN184957B (ru)
MA (1) MA23770A1 (ru)
MX (1) MX9705142A (ru)
NO (3) NO973167L (ru)
NZ (1) NZ301204A (ru)
OA (1) OA10738A (ru)
PL (1) PL322249A1 (ru)
PT (1) PT809499E (ru)
RU (2) RU2196139C2 (ru)
SI (1) SI0809499T1 (ru)
SK (1) SK90297A3 (ru)
TW (1) TW523511B (ru)
WO (1) WO1996021452A1 (ru)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
EP0724588B1 (en) * 1993-09-17 1999-11-10 Smithkline Beecham Corporation Drug binding protein
US6203803B1 (en) 1994-12-14 2001-03-20 Societe L'oreal S.A. Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
EP0802908A4 (en) * 1995-01-12 2001-04-11 Smithkline Beecham Corp NEW CONNECTIONS
EP0737471A3 (fr) * 1995-04-10 2000-12-06 L'oreal Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
US6369068B1 (en) 1995-06-07 2002-04-09 Smithkline Beecham Corporation Amino substituted pyrimidine containing compounds
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
US5658903A (en) * 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
FR2740341B1 (fr) * 1995-10-26 1997-12-19 Oreal Utilisation de sel de lanthanide, d'etain, de zinc, de manganese, d'yttrium, de cobalt, de baryum, de strontium dans une composition pour la peau
ZA9610687B (en) * 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
US5977103A (en) * 1996-01-11 1999-11-02 Smithkline Beecham Corporation Substituted imidazole compounds
ZA97175B (en) 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
AP9700912A0 (en) * 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
JP2000507224A (ja) * 1996-03-08 2000-06-13 スミスクライン・ビーチャム・コーポレイション Csaid化合物の血管形成の抑制物質としての使用
JP2000507558A (ja) * 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション Cns損傷についての新規な治療
EP0956018A4 (en) * 1996-08-21 2000-01-12 Smithkline Beecham Corp IMIDAZOLE COMPOUNDS, COMPOSITIONS CONTAINING THEM AND THEIR USE
DK0948495T3 (da) 1996-11-19 2004-06-01 Amgen Inc Aryl- og heteroarylsubstitueret, kondenseret pyrrol som antiinflammatoriske midler
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
AP999A (en) * 1997-01-10 2001-08-11 Smithkline Beecham Corp Novel substituted imidazole compounds.
US5929076A (en) * 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
US6432947B1 (en) * 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
PL191111B1 (pl) 1997-04-24 2006-03-31 Ortho Mcneil Pharm Inc Podstawione imidazole, sposób ich wytwarzania, kompozycje zawierające podstawione imidazole oraz ich zastosowanie
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
RU2249591C2 (ru) * 1997-05-22 2005-04-10 Дж.Д. Серл Энд Ко. 3(5)-гетероарилзамещенные пиразолы в качестве ингибиторов киназы p38
CA2288787A1 (en) 1997-05-22 1998-11-26 G.D. Searle And Co. Pyrazole derivatives as p38 kinase inhibitors
TR200000235T2 (tr) * 1997-05-22 2000-05-22 G.D. Searle &Co. p38 kinaz inhibitörleri olarak ikame edilmiş pirazoller.
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6087496A (en) 1998-05-22 2000-07-11 G. D. Searle & Co. Substituted pyrazoles suitable as p38 kinase inhibitors
SK286940B6 (sk) 1997-06-12 2009-07-06 Aventis Pharma Limited Spôsob prípravy imidazolového derivátu
AU7966198A (en) 1997-06-13 1998-12-30 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
WO1998057966A1 (en) 1997-06-19 1998-12-23 Smithkline Beecham Corporation Novel aryloxy substituted pyrimidine imidazole compounds
EP0994858A1 (en) * 1997-06-30 2000-04-26 Ortho-McNeil Pharmaceutical, Inc. 2-substituted imidazoles useful in the treatment of inflammatory diseases
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
US7301021B2 (en) * 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
AR016294A1 (es) * 1997-07-02 2001-07-04 Smithkline Beecham Corp Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion
US6251914B1 (en) 1997-07-02 2001-06-26 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
WO1999017776A1 (en) * 1997-10-08 1999-04-15 Smithkline Beecham Corporation Novel cycloalkenyl substituted compounds
EP1021173A1 (en) * 1997-10-10 2000-07-26 Imperial College Innovations Limited Use of csaid?tm compounds for the management of uterine contractions
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US7041694B1 (en) 1997-12-17 2006-05-09 Cornell Research Foundation, Inc. Cyclooxygenase-2 inhibition
US6335340B1 (en) 1997-12-19 2002-01-01 Smithkline Beecham Corporation compounds of heteroaryl substituted imidazole, their pharmaceutical compositons and uses
KR20010025087A (ko) 1998-05-22 2001-03-26 스튜어트 알. 수터 신규한 2-알킬 치환된 이미다졸 화합물
JP2002516325A (ja) * 1998-05-26 2002-06-04 スミスクライン・ビーチャム・コーポレイション 新規な置換イミダゾール化合物
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
AU4395399A (en) * 1998-07-02 2000-01-24 Sankyo Company Limited Five-membered heteroaryl compounds
US6207687B1 (en) * 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
US6599910B1 (en) * 1998-08-20 2003-07-29 Smithkline Beecham Corporation Substituted triazole compounds
JP2002528506A (ja) * 1998-11-04 2002-09-03 スミスクライン・ビーチャム・コーポレイション ピリジン−4−イルまたはピリミジン−4−イル置換ピラジン
US6239279B1 (en) 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
WO2000040243A1 (en) 1999-01-08 2000-07-13 Smithkline Beecham Corporation Novel compounds
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
WO2000078757A1 (en) * 1999-06-17 2000-12-28 Shionogi Bioresearch Corp. Inhibitors of il-12 production
IL137365A0 (en) * 1999-07-21 2001-07-24 Sankyo Co Heteroaryl-substituted pyrrole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
JP2003514899A (ja) 1999-11-23 2003-04-22 スミスクライン・ビーチャム・コーポレイション CSBP/p38キナーゼ阻害剤としての3,4‐ジヒドロ−(1H)−キナゾリン−2−オン化合物
DE60023025T2 (de) 1999-11-23 2006-07-13 Smithkline Beecham Corp. 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
AU1783201A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
IL144760A0 (en) * 1999-12-08 2002-06-30 Pharmacia Corp Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
US20020002169A1 (en) * 1999-12-08 2002-01-03 Griffin John H. Protein kinase inhibitors
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US6525051B2 (en) 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
US20020128267A1 (en) * 2000-07-13 2002-09-12 Rebanta Bandyopadhyay Method of using COX-2 inhibitors in the treatment and prevention of ocular COX-2 mediated disorders
PT1303265E (pt) 2000-07-20 2007-10-09 Lauras As ''utilização de inibidores da cox-2 como imuno-estimulantes, no tratamento do vih ou da sida''
IL155367A0 (en) * 2000-10-23 2003-12-23 Smithkline Beecham Corp NOVEL 2,4,8-TRISUBSTITUTED-8h-PYRIDO[2,3,-d]PYRIMIDIN-7-ONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, PROCESSES FOR THE PREPARATION THEREOF, AND USE THEREOF IN THE PREPARATION OF MEDICAMENTS FOR TREATING CSBP/p38 KINASE MEDIATED DISEASES
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
ES2296910T3 (es) * 2001-01-22 2008-05-01 Sankyo Company, Limited Compuestos sustituidos con grupo amino biciclicos.
BR0208462A (pt) 2001-03-26 2004-03-02 Ortho Mcneil Pharm Inc Processo para a preparação de derivados imidazólicos e novas estruturas cristalinas dos mesmos
US7695736B2 (en) 2001-04-03 2010-04-13 Pfizer Inc. Reconstitutable parenteral composition
WO2002094267A1 (en) * 2001-05-24 2002-11-28 Sankyo Company, Limited Pharmaceutical composition for prevention or treatment of arthritis
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
MY147948A (en) * 2001-10-22 2013-02-15 Mitsubishi Tanabe Pharma Corp 4- imidazolin-2-one compounds
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
US6982259B2 (en) * 2002-04-30 2006-01-03 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
DE60310730T2 (de) 2002-07-09 2007-05-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege
AU2003262911A1 (en) 2002-08-29 2004-03-19 Scios Inc. Methods of promoting osteogenesis
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
UA80296C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
JP4654035B2 (ja) 2002-11-05 2011-03-16 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗菌剤
BR0317313A (pt) * 2002-12-16 2005-11-08 Astrazeneca Uk Ltd Processo para a preparação de um composto, e, composto
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
CL2004000366A1 (es) * 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
US7244441B2 (en) 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
SV2005001973A (es) * 2003-12-12 2005-11-04 Wyeth Corp Quinolinas utiles en el tratamiento de enfermedades cardiovasculares ref. wyth0090-504 (am101500)
JP2007514730A (ja) * 2003-12-18 2007-06-07 ファイザー・プロダクツ・インク p38MAPキナーゼ阻害剤による、動物における急性の炎症の治療方法
RU2401265C2 (ru) * 2004-06-10 2010-10-10 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназы
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
WO2006025373A1 (ja) * 2004-08-31 2006-03-09 Sanyo Chemical Industries, Ltd. 界面活性剤
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
JP2008537937A (ja) * 2005-03-25 2008-10-02 グラクソ グループ リミテッド ピリド[2,3−d]ピリミジン−7−オンおよび3,4−ジヒドロピリミド[4,5−d]ピリミジン−2(1H)−オン誘導体の製造方法
PE20100737A1 (es) * 2005-03-25 2010-11-27 Glaxo Group Ltd Nuevos compuestos
US20060252807A1 (en) * 2005-04-22 2006-11-09 Kalypsys, Inc. Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
PL2021335T3 (pl) 2006-04-20 2011-10-31 Janssen Pharmaceutica Nv Związki heterocykliczne jako inhibitory kinazy C-FMS
WO2007124322A1 (en) 2006-04-20 2007-11-01 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
WO2008151307A2 (en) * 2007-06-05 2008-12-11 The Regents Of The University Of Colorado T-cell cytokine-inducing surface molecules and methods of use
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
WO2010091324A1 (en) * 2009-02-06 2010-08-12 Western States Biopharmaceuticals, Inc. Dual inhibition of immunophilin/cyclophilin and emmprin immunoglobulin receptor superfamily members
RU2418582C1 (ru) * 2010-04-08 2011-05-20 Аверин Константин Михайлович 1,3-диалкилбензимидазолия галогениды - средства для лечения рассеянного склероза
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
JP6359537B2 (ja) 2012-08-07 2018-07-18 ヤンセン ファーマシューティカ エヌ.ベー. 複素環エステル誘導体の調製プロセス
EA201590380A1 (ru) * 2012-08-16 2015-07-30 Янссен Фармацевтика Нв Замещенные пиразолы, используемые в качестве блокаторов кальциевых каналов n-типа
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
CN104402823B (zh) * 2014-11-05 2016-03-23 上海浩登材料科技有限公司 一种1,2-二甲基咪唑的制备方法
CN104496906B (zh) * 2014-11-05 2016-03-23 上海浩登材料科技有限公司 一种咪唑的制备方法
EP4591936A3 (en) 2015-03-23 2025-10-15 Tianli Biotech Pty Ltd Treatment of respiratory diseases
US20200079757A1 (en) * 2017-05-03 2020-03-12 The University Of Melbourne Compounds for the treatment of respiratory diseases
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
PT3691620T (pt) 2017-10-05 2022-10-06 Fulcrum Therapeutics Inc Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd
WO2020093098A1 (en) * 2018-11-07 2020-05-14 The University Of Melbourne Novel compounds for the treatment of respiratory diseases
EP3725768A1 (en) * 2019-04-17 2020-10-21 Newron Pharmaceuticals S.p.A. Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives
FR3097222B1 (fr) * 2019-06-11 2021-05-28 Michelin & Cie Nouveaux composes 1,3-dipolaires comprenant un heterocycle aromatique et un cycle imidazole
MX2022002017A (es) 2019-08-23 2022-03-11 Mochida Pharm Co Ltd Metodo para producir derivado de heterociclideno acetamida.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES377330A1 (es) * 1969-03-11 1972-06-16 Glaxo Lab Ltd Procedimiento para preparar esteres de acido 7 beta-acila- mido-3-metilcef3-em-4-carboxilico.
US3707475A (en) * 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3929807A (en) * 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
US3940486A (en) * 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US4058614A (en) * 1973-12-04 1977-11-15 Merck & Co., Inc. Substituted imidazole compounds and therapeutic compositions therewith
CY1302A (en) * 1978-04-11 1985-12-06 Ciba Geigy Ag Mercapto-imidazole derivatives,their preparation,their pharmaceutical compositions and applications
US4199592A (en) * 1978-08-29 1980-04-22 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-2-nitroimidazoles
DD201677A5 (de) * 1980-07-25 1983-08-03 Ciba Geigy Verfahren zur herstellung von trisubstituierten imidazolderivaten
US4503065A (en) * 1982-08-03 1985-03-05 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl 1-2-halo imidazoles
US4565875A (en) * 1984-06-27 1986-01-21 Fmc Corporation Imidazole plant growth regulators
US4686231A (en) * 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
IE59893B1 (en) * 1986-04-16 1994-04-20 Roussel Uclaf Process for the manufacture of n-(sulfonylmethyl) formamides
IL83467A0 (en) * 1986-08-15 1988-01-31 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
US5166400A (en) * 1989-01-19 1992-11-24 Pfizer Inc. Intermediates for isopropyl 3S-amino-2R-hydroxy-alkanoates
AU9137591A (en) * 1990-12-13 1992-07-08 Smithkline Beecham Corporation Novel csaids
WO1992010498A1 (en) * 1990-12-13 1992-06-25 Smithkline Beecham Corporation Novel csaids
AU3592493A (en) * 1992-01-13 1993-08-03 Smithkline Beecham Corporation Pyridyl substituted imidazoles
IL104369A0 (en) * 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
AU7629594A (en) * 1993-07-21 1995-02-20 Smithkline Beecham Corporation Imidazoles for treating cytokine mediated disease
IL114483A0 (en) * 1994-07-12 1995-11-27 Yissum Res Dev Co Glycinamide derivatives pharmaceutical compositions containing the same and methods utilizing the same
EP0802908A4 (en) * 1995-01-12 2001-04-11 Smithkline Beecham Corp NEW CONNECTIONS

Also Published As

Publication number Publication date
HK1003623A1 (en) 1999-02-12
NZ301204A (en) 1999-05-28
TW523511B (en) 2003-03-11
IL134324A0 (en) 2001-04-30
IN188339B (ru) 2002-09-07
IL116455A0 (en) 1996-03-31
MA23770A1 (fr) 1996-10-01
FI972901A0 (fi) 1997-07-08
IL134323A0 (en) 2001-04-30
PT809499E (pt) 2004-04-30
CA2209938A1 (en) 1996-07-18
JP3330952B2 (ja) 2002-10-07
RU2196139C2 (ru) 2003-01-10
US5663334A (en) 1997-09-02
MX9705142A (es) 1997-10-31
BR9606904A (pt) 1997-10-21
ES2210348T3 (es) 2004-07-01
WO1996021452A1 (en) 1996-07-18
FI972901A7 (fi) 1997-09-08
US20020188122A1 (en) 2002-12-12
HUP9702409A2 (hu) 1999-05-28
IL134322A0 (en) 2001-04-30
ATE254613T1 (de) 2003-12-15
US6103936A (en) 2000-08-15
ID23597A (id) 1996-10-10
EP0809499A1 (en) 1997-12-03
IN188338B (ru) 2002-09-07
IL134323A (en) 2001-11-25
HUP9702409A3 (en) 1999-06-28
JPH10512555A (ja) 1998-12-02
NO973167D0 (no) 1997-07-08
JP2002105047A (ja) 2002-04-10
IN184957B (ru) 2000-10-07
IL134322A (en) 2001-09-13
IL134324A (en) 2001-08-26
EP0809499B1 (en) 2003-11-19
CN1138546C (zh) 2004-02-18
EP1264827A1 (en) 2002-12-11
DE69630777D1 (de) 2003-12-24
AR002267A1 (es) 1998-03-11
AP1270A (en) 2004-04-16
SK90297A3 (en) 1998-01-14
NO973167L (no) 1997-09-08
NO20016225D0 (no) 2001-12-19
AP9701021A0 (en) 1997-07-31
PL322249A1 (en) 1998-01-19
AU4657296A (en) 1996-07-31
CZ215897A3 (cs) 1998-04-15
FI972901L (fi) 1997-09-08
IL116455A (en) 2001-07-24
ID23599A (id) 1996-10-10
DE69630777T2 (de) 2004-07-29
BG101727A (bg) 1998-03-31
NO20016226D0 (no) 2001-12-19
US6222036B1 (en) 2001-04-24
US5593992A (en) 1997-01-14
NO20016226L (no) 1997-09-08
DK0809499T3 (da) 2004-03-29
EP0809499A4 (en) 1998-10-14
DZ1961A1 (fr) 2002-02-17
NO20016225L (no) 1997-09-08
AU705207C (en) 2002-09-19
SI0809499T1 (en) 2004-04-30
ID23273A (id) 1996-10-10
CN1177299A (zh) 1998-03-25
BG63769B1 (bg) 2002-12-29
AU705207B2 (en) 1999-05-20
OA10738A (en) 2002-12-11

Similar Documents

Publication Publication Date Title
RU2002122174A (ru) Способ профилактики и лечения заболевания, опосредуемого csbp/rk/p38 киназой, и способ лечения воспаления
ES2337254T3 (es) Derivados de carboxamida.
HRP20210769T1 (hr) Supstituirani 3-azabiciklo[3.1.0]heksani kao inhibitori ketoheksokinaze
RU2006108867A (ru) Модуляторы активности рецептора хемокина
US6228881B1 (en) Aromatic heterocyclic compounds and their use as anti-inflammatory agents
RU2006134020A (ru) Конденсированные производные пиразола
JP2005539000A5 (ru)
RU2018120242A (ru) Хинолиновые соединения, способы их получения и их применения в качестве лекарственного средства, ингибирующего транспортер уратов
JP2002516314A5 (ru)
JP2004529911A5 (ru)
NO20062489L (no) Heterocykliske anti-migrenemidler
NO20020384D0 (no) Amin og aminderivater som ligander for neuropeptid Y Y5 reseptor anvendelig ved behandling av fedme og andre forstyrrelser
JP2008513516A5 (ru)
US4820710A (en) Benzimidazole derivatives and pharmaceutical compositions containing them
HRP20120900T1 (hr) Inhibitori p38 kinaze bazirani na peteroäślanom heterociklu
NZ336861A (en) Benzo-2-triazole substituted compounds, pharmaceutical compositions, and process for preparation as IL-8 receptor antagonists
WO2003047516A3 (en) Pyrimidine compounds
JP2007509947A5 (ru)
JP2015503505A5 (ru)
KR950702964A (ko) 세로토닌 길항제로서의 N-시아노-N'-피리딜구아니딘(N-cyano-N'-pyridylguanidines as serotonin antagonists)
JP2014524918A5 (ru)
RU2005108667A (ru) Производные n-биарилметиламиноциклоалканкарбоксамида
DK0637586T3 (da) 2-(Piperidin-4-yl, pyridin-4-yl og tetrahydropyridin-4-yl)-benzofuran-7-carbamatderivater, deres fremstilling og anvendelse
CA2158910A1 (en) B3-Adrenoceptor Agonists and Antagonists for the Treatment of Intestinal Motility Disorders, Depression, Prostate Disease and Dyslipidemia
JP2003531144A5 (ru)

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20060110